Cargando…

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia

Olanzapine is a commonly used drug in the treatment of schizophrenia, but its clinical application has been restricted by metabolic-related side effects. In order to mitigate the weight gain side effects caused by olanzapine, other drugs with different targets were selected for combined use and eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Lingzhi, Ren, Xia, Xu, Junyi, Ma, Yurong, Xue, Yunlin, Zhuang, Tao, Zhang, Guisen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024832/ https://www.ncbi.nlm.nih.gov/pubmed/35458749 http://dx.doi.org/10.3390/molecules27082550

Ejemplares similares

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice
por: Ren, Xia, et al.
Publicado: (2022)

M208. MEASURES OF COGNITION AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS RECEIVING SEP-363856
por: Milanovic, Snezana, et al.
Publicado: (2020)

Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856
por: Begni, Veronica, et al.
Publicado: (2021)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans
por: Hopkins, Seth C., et al.
Publicado: (2021)

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
por: Ågren, Richard, et al.
Publicado: (2023)

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP-363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP- 363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Synergistic Antinociceptive Effects of Indomethacin–Pregabalin and Meloxicam–Pregabalin in Paclitaxel-Induced Neuropathic Pain
por: Ma, Yurong, et al.
Publicado: (2022)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Effects of olanzapine on anhedonia in schizophrenia: mediated by complement factor H
por: Zhang, Yi, et al.
Publicado: (2023)

Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients
por: Liang, Mining, et al.
Publicado: (2019)

Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia
por: Katshu, Mohammad Zia Ul Haq, et al.
Publicado: (2018)

Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function
por: Yang, Lujie, et al.
Publicado: (2021)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review
por: Xue, Hai Bo Haber, et al.
Publicado: (2014)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang, Fuyin, et al.
Publicado: (2018)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
por: Shoja Shafti, Saeed, et al.
Publicado: (2014)

Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia
por: Tajiri, Misuzu, et al.
Publicado: (2018)

Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
por: Hindmarsh, Jonathan, et al.
Publicado: (2020)

Prevalence of diabetes in patients of Schizophrenia on long-term use of olanzapine
Publicado: (2022)

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients
por: Zhou, Wei, et al.
Publicado: (2019)

Cine difusión Sep
Publicado: (1975)

Dysmorphic Delusion and Olanzapine-Induced Postpartum Dermatosis in a Case of Schizophrenia
por: Sutar, Roshan, et al.
Publicado: (2019)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome, Leslie, et al.
Publicado: (2019)

Sexual dysfunction in male schizophrenia remitted patients treated with risperidone and olanzapine
Publicado: (2022)

Effect of Haloperidol and Olanzapine on Hippocampal Cells’ Proliferation in Animal Model of Schizophrenia
por: Osacka, Jana, et al.
Publicado: (2022)

High-dose olanzapine in treatment-resistant schizophrenia: a systematic review
por: Gannon, Louisa, et al.
Publicado: (2023)

Partial Functional Diversification of Drosophila melanogaster Septin Genes Sep2 and Sep5
por: O’Neill, Ryan S., et al.
Publicado: (2016)

Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy
por: Fang, Xinyu, et al.
Publicado: (2020)

La SEP à Wiesbaden
Publicado: (1972)

LHC Meeting, Sep. 1998
por: Llewellyn Smith, Christopher Hubert, et al.
Publicado: (1998)

Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters
por: Lu, Mong-Liang, et al.
Publicado: (2013)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia
por: Kulkarni, Gajanan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8ged37pr6q2238k9aleve6i777